Oxygenating Innovation
30-06-2024 – Our alumni project, OxyPrem (now OxyPrem AG), was recently featured in Ticino Management, a Lugano-based publication.
"Our aim was clear from the outset, to provide immediate help to doctors by alerting the medical team immediately when oxygen levels fall outside the parameters indicated as safe. This information allows early intervention, and prevents possible irreversible brain damage or disability in newborns", shares Alexander Nitsch, CEO of OxyPrem AG
One in ten babies are born prematurely on average. Complications resulting from unstable oxygen regulation in brain tissue pose serious risks: 46% of babies who survive a severe premature birth have permanent health problems.
During Oxyprem's acceleration at Wyss Zurich, the team launched OxyPrem 1.4, a CE-certified product, which was distributed to 35 specialised hospitals in Europe and India and successfully used on more than 300 patients.
With the introduction of this novel technology, the team was able to gather valuable feedback and guidance from field experts, contributing to the development of a second-generation product that is more efficient and adapted to the needs of premature infants and medical staff. The new generation device, also known as NOAH - Neo -natal Oxygenation and Health, is planned for launch in early 2025.
Currently the article is available only in Italian.
